Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Public ClinicalTrials.gov record NCT04463771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Study identification
- NCT ID
- NCT04463771
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Interventions
- retifanlimab Drug
- epacadostat Drug
- pemigatinib Drug
- INCAGN02385 Drug
- INCAGN02390 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 26, 2021 (Actual)
- Primary completion
- May 29, 2026 (Actual)
- Completion
- May 29, 2026 (Actual)
- Last update posted
- Jun 11, 2026
2021 – 2026
United States locations
- U.S. sites
- 29
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Womens Cancer Care Akwcc | Anchorage | Alaska | 99508 | — |
| Honorhealth | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| UCLA Medical Hematology & Oncology | Los Angeles | California | 90048 | — |
| Olive View Med Ctr | Sylmar | California | 91342 | — |
| Broward Health Medical Center | Fort Lauderdale | Florida | 33316 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Mount Sinai Medical Center Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Advent Health Medical Group-Orlando 2501 | Orlando | Florida | 32804 | — |
| H. Lee Moffitt Cancer Center and Research Institute Hospital | Tampa | Florida | 33612-9497 | — |
| Georgia Cancer Center | Augusta | Georgia | 30912 | — |
| Barbara Ann Karmanos Cancer Hospital | Detroit | Michigan | 48201 | — |
| Minnesota Oncology-Maplewood | Coon Rapids | Minnesota | 55433 | — |
| Midwest Cancer Care | Kansas City | Missouri | 64132 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89074 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87131 | — |
| Laura & Isaac Perlmutter Cancer Ctr | New York | New York | 10016 | — |
| University of North Carolina At Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| The Ohio State University Wexner Medical Center Division of Gynecologic Oncology | Hilliard | Ohio | 43026 | — |
| Willamette Valley Cancer Institute | Eugene | Oregon | 97401-8122 | — |
| Texas Oncology-Tyler | Sioux Falls | South Dakota | 57104 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Austin Center | Austin | Texas | 78731 | — |
| Texas Oncology-Fort Worth South Henderson | Fort Worth | Texas | 76104-3902 | — |
| Texas Oncology San Antonio | San Antonio | Texas | 78240 | — |
| Texas Oncology the Woodlands | Shenandoah | Texas | 77380 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04463771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04463771 live on ClinicalTrials.gov.